{"transactions":[{"id":748699,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T22:16:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":32996,"price":6.15,"value":202925.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":32996,"derivative":{"exercise_price":6.15,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":32996},"source":{"system":"sec-edgar","filing":"0001916987-26-000004","document":"wk-form4_1780697773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000191698726000004/wk-form4_1780697773.xml","form_type":"4"}},{"id":748698,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T22:16:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date."}],"balance_after":113359,"source":{"system":"sec-edgar","filing":"0001916987-26-000004","document":"wk-form4_1780697773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000191698726000004/wk-form4_1780697773.xml","form_type":"4"}},{"id":823501,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:54:24.000Z","date":"2026-03-30","kind":"sale","planned":true,"acquired":false,"shares":10834,"price":5.5414,"value":60035.5276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.290 to $5.630, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":89166,"source":{"system":"sec-edgar","filing":"0001916987-26-000002","document":"wk-form4_1775080462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000191698726000002/wk-form4_1775080462.xml","form_type":"4"}},{"id":1021806,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.9338,"expiration_date":"2034-04-28","underlying":"Ordinary Shares","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021805,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":96000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":2.67,"expiration_date":"2033-04-27","underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021804,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":288000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.6025,"expiration_date":"2032-03-13","underlying":"Ordinary Shares","underlying_shares":288000},"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021803,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"exercise","planned":false,"acquired":false,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021802,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021801,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"exercise","planned":false,"acquired":true,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award (\"RSU Award\"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration."}],"balance_after":72000,"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1021800,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-08T20:32:20.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23176,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the \"Scheme of Arrangement\") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the \"Transaction Agreement\"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (\"Bidco\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the \"ADS Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-097946","document":"tm2528014-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925097946/tm2528014-3_4seq1.xml","form_type":"4"}},{"id":1075448,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:24:07.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":72000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-25-074391","document":"tm2522566-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925074391/tm2522566-7_4seq1.xml","form_type":"4"}},{"id":1075447,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-06T00:24:07.000Z","date":"2025-08-01","kind":"sale","planned":false,"acquired":false,"shares":824,"price":13.1437,"value":10830.4088,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of the restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the sale price of the ADSs divided by eight (8)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Consists of 23,176 Ordinary Shares represented by 2,897 ADSs."}],"balance_after":23176,"source":{"system":"sec-edgar","filing":"0001104659-25-074391","document":"tm2522566-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925074391/tm2522566-7_4seq1.xml","form_type":"4"}},{"id":1075446,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-06T00:24:07.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reported securities are represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001104659-25-074391","document":"tm2522566-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925074391/tm2522566-7_4seq1.xml","form_type":"4"}},{"id":1164377,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-04-29T21:09:17.000Z","date":"2025-04-25","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of Restricted Share Units (\"RSUs\") covering American Depositary Shares (\"ADSs\"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Share Units (\"RSUs\") covering American Depositary Shares (\"ADSs\"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of Restricted Share Units (\"RSUs\") covering American Depositary Shares (\"ADSs\"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Share Units (\"RSUs\") covering American Depositary Shares (\"ADSs\"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date."}],"balance_after":96000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001104659-25-041387","document":"tm2513544-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465925041387/tm2513544-2_4seq1.xml","form_type":"4"}},{"id":1189191,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T20:45:00.000Z","date":"2025-03-28","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001867096-25-000058","document":"wk-form4_1743194694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000186709625000058/wk-form4_1743194694.xml","form_type":"4"}},{"id":1533196,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2024-04-30T20:15:40.000Z","date":"2024-04-29","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":240000,"derivative":{"exercise_price":1.9338,"expiration_date":"2034-04-28","underlying":"Ordinary Shares","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-24-054942","document":"tm2412993-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465924054942/tm2412993-1_4seq1.xml","form_type":"4"}},{"id":1911667,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2023-04-28T20:16:54.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":96000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-04-27","underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001104659-23-052990","document":"tm2314094-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465923052990/tm2314094-1_4seq1.xml","form_type":"4"}},{"id":2331655,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":41105,"kind":"person","name":"Brady James Aloysius","position":1,"cik":"0001916987","reported_name":"Brady James Aloysius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2022-03-16T10:04:18.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":288000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on August 1, 2022, 25% on November 1, 2022, 25% on February 1, 2023 and 25% on May 1, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":288000,"derivative":{"exercise_price":0.6025,"expiration_date":"2032-03-13","underlying":"Ordinary Shares","underlying_shares":288000},"source":{"system":"sec-edgar","filing":"0001104659-22-034156","document":"tm229323-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916987/000110465922034156/tm229323-2_4seq1.xml","form_type":"4"}}]}